Electromed, Inc.
AMEX•ELMD
CEO: Mr. James L. Cunniff
セクター: Healthcare
業種: Medical - Devices
上場日: 2010-08-13
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
連絡先情報
時価総額
$234.04M
PER (TTM)
28.5
3.6
配当利回り
--
52週高値
$34.23
52週安値
$17.73
52週レンジ
順位24Top 10.8%
5.7
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q2 2026 データ
売上高
$18.90M+0.00%
直近4四半期の推移
EPS
$0.33+0.00%
直近4四半期の推移
フリーCF
$3.29M+0.00%
直近4四半期の推移
2026 Q1 決算ハイライト
主なハイライト
Revenue Growth Strong Net revenues totaled $16.89M USD for the quarter, increasing 15.1% compared to prior period.
Net Income Surges 44.9% Net income reached $2.14M USD, driven by increased revenue and gross profit performance.
Hospital Sales Accelerate Hospital revenue grew substantially by 51.7% to $1.05M USD due to increased sales focus.
Basic EPS Improvement Basic earnings per share increased to $0.26 USD from $0.17 USD in the prior year period.
リスク要因
Operating Cash Flow Decline Net cash provided by operating activities fell significantly to $169K USD from $2.31M USD.
Working Capital Shifts Large $2.35M decrease in accrued compensation negatively impacted cash provided by operations.
Inventory Investment Inventories increased by $515K USD during the quarter, consuming operational cash resources.
Credit Facility Maturity Revolving line of credit for $2.5M USD is set to expire in December 2025, requiring renewal.
見通し
Liquidity Forecast Positive Working capital of $35.8M USD and available credit expected to meet liquidity needs for twelve months.
Share Repurchase Activity Company utilized $1.00M USD to repurchase common stock under the recently approved authorization.
SG&A Expense Increase SG&A expenses rose 9.6% due to higher sales headcount and ongoing compensation benchmarking efforts.
Tax Legislation Evaluation Evaluating impact of OBBBA legislation regarding deductibility of U.S.-based research expenditures.
同業比較
売上高 (TTM)
ARAY$436.97M
INGN$347.03M
HCAT$316.06M
粗利益率 (最新四半期)
MXCT92.4%
86.8%
86.4%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CATX | $352.36M | -3.3 | -39.1% | 1.1% |
| VMD | $321.53M | 23.5 | 10.1% | 12.2% |
| SGHT | $305.07M | -6.6 | -61.6% | 35.0% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
6.4%
安定成長
4四半期純利益CAGR
13.4%
収益性の着実な向上
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月11日
EPS:-
|売上高:-
財務レポート
財務データ
全年度
Form 10-Q - Q2 2026
会計期末: 2025年12月31日|提出日: 2026年2月10日|売上高: $18.90M+0.0%|EPS: $0.33+0.0%予想を上回るForm 10-Q - Q1 2026
会計期末: 2025年9月30日|提出日: 2025年11月12日|売上高: $16.89M+15.1%|EPS: $0.26+52.9%予想を上回るForm 10-K - FY 2025
会計期末: 2025年6月30日|提出日: 2025年8月26日|売上高: $64.00M+17.0%|EPS: $0.90+50.0%予想を上回るForm 10-Q - Q3 2025
会計期末: 2025年3月31日|提出日: 2025年5月13日|売上高: $15.68M+13.1%|EPS: $0.22+29.4%予想を上回るForm 10-Q - Q2 2025
会計期末: 2024年12月31日|提出日: 2025年2月11日|売上高: $16.26M+18.7%|EPS: $0.23+15.0%予想を上回るForm 10-Q - Q1 2025
会計期末: 2024年9月30日|提出日: 2024年11月12日|売上高: $14.67M+19.0%|EPS: $0.17+834.1%予想を上回るForm 10-K - FY 2024
会計期末: 2024年6月30日|提出日: 2024年8月27日|売上高: $54.72M+13.8%|EPS: $0.60+62.2%予想を上回るForm 10-Q - Q3 2024
会計期末: 2024年3月31日|提出日: 2024年5月7日|売上高: $13.87M+14.9%|EPS: $0.17+30.8%予想を上回る